Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621001065886
Ethics application status
Approved
Date submitted
6/07/2021
Date registered
12/08/2021
Date last updated
7/02/2022
Date data sharing statement initially provided
12/08/2021
Type of registration
Prospectively registered
Titles & IDs
Public title
Testing a new method for measuring lymphatic fluid using blood sampling.
Query!
Scientific title
Measuring Thoracic Duct Lymph Composition during Acute and Critical Illness: A Novel Central Venous Sampling Technique.
Query!
Secondary ID [1]
304707
0
None
Query!
Universal Trial Number (UTN)
U1111-1267-5582
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Lymphatic sampling in acute and critical illness patients
322726
0
Query!
Condition category
Condition code
Cardiovascular
320315
320315
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Central venous sampling for measurement of thoracic duct lymph composition.
The study is a pilot cohort study to confirm the feasibility of a novel technique to measure changes in venous blood due to thoracic duct lymph drainage. The plan is to recruit 10 patients in the Cardiovascular ICU unit in Auckland City Hospital, who are undergoing pre-planned elective cardiac surgery and will act as their own control. Peripheral and central venous catheters are inserted as part of normal surgical procedure. In addition to this, after the surgery the cardiac anaesthetist will insert an enteral feeding tube and a second central venous catheter into the left internal jugular vein (around where the thoracic duct joins the vein) above the pre-inserted catheter. Blood will be sampled using syringes by a research team member or a research nurse from the peripheral catheter and the two central catheters. Blood is taken and compared across two different timepoints (end-inspiration and end-expiration). The sampling procedure is done twice over 2 hours (before and after ingestion of lipid-rich cream via the feeding tube to promote lymph flow). The blood will be analysed for lymphatic biomarker concentrations. Consent from the patients will be obtained prior to the surgery, and the study procedures will be conducted post-surgery while the patient is still under anaesthetic and on ventilator. No further contribution is needed from the patient once the blood samples have been taken.
Query!
Intervention code [1]
321090
0
Treatment: Other
Query!
Comparator / control treatment
No control group. Patients will act as their own control.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
328164
0
Detection of a difference between central blood samples in the concentration of Apolipoprotein ApoB48 (lymphatic biomarker) using an ELISA ApoB48 assay.
Query!
Assessment method [1]
328164
0
Query!
Timepoint [1]
328164
0
Post surgery, when the patient is in the post-surgical ward but still under anaesthetic, the blood samples will be collected. Simultaneous sampling will be performed using syringes attached to the relevant catheters. During end-inspiration, blood will be drawn simultaneously from each catheter. This is done until a total of 2.5mL of blood is obtained from each catheter. The syringes are then replaced and the procedure is repeated at end-expiration.
Lipid-rich cream will then be administered via a nasogastric/enteral feeding tube.
After waiting 30mins to allow for uptake of the lipids into the lymphatic system, sampling will be repeated for both end-inspiration and end-expiration to obtain "post-cream" samples.
After all blood samples have been taken from the patient, they will be taken to be centrifuged to separate the plasma, which will be stored in a -80°C freezer in the hospital.
Once plasma from 10 patients has been collected (done within ~1 month), the samples will be transferred to labs at the University of Auckland to be analysed.
Query!
Primary outcome [2]
328165
0
Detection of a difference in Total Triglyceride concentration between central blood samples via a lipid profile analysis.
Query!
Assessment method [2]
328165
0
Query!
Timepoint [2]
328165
0
When the patient is in the post-surgical ward but still under anaesthetic, the blood samples will be collected. During end-inspiration, blood will be drawn simultaneously from each catheter. This is done until a total of 2.5mL of blood is obtained from each catheter. The procedure is then repeated at end-expiration.
Lipid-rich cream will then be administered via a nasogastric/enteral feeding tube.
After waiting 30mins to allow for uptake of the lipids into the lymphatic system, sampling will be repeated for both end-inspiration and end-expiration to obtain "post-cream" samples.
After all blood samples have been taken from the patient, they will be taken to be centrifuged to separate the plasma, which will be stored in a -80°C freezer in the hospital.
Once plasma from 10 patients has been collected (done within ~1 month), the samples will be transferred to labs at the University of Auckland to be analysed.
Query!
Secondary outcome [1]
397907
0
Nil
Query!
Assessment method [1]
397907
0
Query!
Timepoint [1]
397907
0
Nil
Query!
Eligibility
Key inclusion criteria
Participant will be recruited from cardiac patients undergoing planned elective surgery (e.g. CABG procedures or similar).
Inclusion criteria:
• Patients aged 18-80 years
• Peripheral venous line
• Multi-lumen left internal jugular or subclavian venous catheter
• NG or NJ tube or willing to have a NG tube placed during anaesthetic to allow the giving of enteral cream to augment TD lymph flow. An existing PEG or PEJ tube would also work.
• Expected to be on mechanical ventilation following the completion of the operation, which is preferred. But the study can be done on patients breathing spontaneously.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
• Pregnancy
• Intrinsic lung disease
• Severe congestive heart failure (leading to high right atrial pressure)
• Moderate-severe tricuspid incompetence (leading to high right atrial pressure)
• Chronic renal/liver conditions
These conditions may affect lymph flow and disrupt the measurement procedure.
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not RCT.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
This study evaluates the outcome of a technique, not clinical outcomes in patients.
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
This small pilot study does not have any precedent, being a novel sampling technique with no preliminary data on which to calculate the power of the study. The decision was that the study 10 patients will be sufficient, as each patient will acts as their own control. The primary endpoint will be any detectable difference in the concentration of lymphatic tracers between the proximal and distal central blood samples at two phases of the respiratory cycle.
The results from the assays will be analysed by statisticians and pharmacokinetic experts in Monash University. Concentration differences between central and peripheral blood samples, as well as between pre and post lipid-ingestion samples will be compared as baseline/background tracer levels in blood. The samples with the greatest difference in concentrations of ApoB48 and TTG levels between proximal and distal samples will be from the timepoint with greatest lymphatic flow and contribution.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
28/02/2022
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
28/03/2022
Query!
Actual
Query!
Date of last data collection
Anticipated
28/03/2022
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
23944
0
New Zealand
Query!
State/province [1]
23944
0
Auckland
Query!
Funding & Sponsors
Funding source category [1]
309077
0
Government body
Query!
Name [1]
309077
0
Health Research Council of New Zealand
Query!
Address [1]
309077
0
Level 3 - ProCARE Building, Grafton Mews, at 110 Stanley Street (GPS: 50 Grafton Road), Grafton, Auckland 1010
New Zealand
Postal address: PO Box 5541, Victoria Street West, Auckland 1142, New Zealand
Query!
Country [1]
309077
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
University of Auckland
Query!
Address
Office of Research Strategy and Integrity
University of Auckland
Private Bag 92019
Auckland Mail Centre
Auckland 1142
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
310023
0
None
Query!
Name [1]
310023
0
Query!
Address [1]
310023
0
Query!
Country [1]
310023
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
308951
0
Health and Disability Ethics Committee (HDEC)
Query!
Ethics committee address [1]
308951
0
Ministry of Health
Health and Disability Ethics Committees
PO Box 5013
Wellington 6140
Query!
Ethics committee country [1]
308951
0
New Zealand
Query!
Date submitted for ethics approval [1]
308951
0
09/08/2021
Query!
Approval date [1]
308951
0
30/09/2021
Query!
Ethics approval number [1]
308951
0
21/NTB/222
Query!
Summary
Brief summary
The overall aim of the project is to evaluate a new technique to sample thoracic duct lymph without relying on direct surgical cannulation. This will allow for a less invasive and more readily available method to determine compositional changes in lymph in patients with critical illness.
The study involves recruiting elective surgical patients in CVICU (cardiovascular intensive care unit) at Auckland City Hospital. Post-elective cardiac surgery, ingestion of lipid rich cream (orally or via nasogastric tube) will promote production of lymph and lymphatic markers such as Apolipoprotein ApoB48 or Triglyceride levels, the increase of which can be detected in blood. Central venous catheters can then be used to sample blood from the Internal Jugular vein upstream and downstream of where the thoracic duct drains into the vein. The blood will then be examined for concentration of lymphatic markers, and differential composition upstream vs downstream will be compared to determine contribution by thoracic duct lymph. Blood sampling will be done at different points in the respiratory cycle to help ascertain period of maximal lymph flow.
The endpoint of the study is to show that this technique is effective in measuring differences in blood concentration due to lymphatic contribution, and that blood sampling can therefore be used to monitor compositional changes in lymph with critical illness.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
112446
0
Prof John Windsor
Query!
Address
112446
0
University of Auckland
Room 2004, Level 2, M&HS Building 507
28 Park Avenue
Grafton
Auckland 1023
Query!
Country
112446
0
New Zealand
Query!
Phone
112446
0
+64 99239791
Query!
Fax
112446
0
Query!
Email
112446
0
[email protected]
Query!
Contact person for public queries
Name
112447
0
Prof John Windsor
Query!
Address
112447
0
University of Auckland
Room 2004, Level 2, M&HS Building 507
28 Park Avenue
Grafton
Auckland 1023
Query!
Country
112447
0
New Zealand
Query!
Phone
112447
0
+64 99239791
Query!
Fax
112447
0
Query!
Email
112447
0
[email protected]
Query!
Contact person for scientific queries
Name
112448
0
Prof John Windsor
Query!
Address
112448
0
University of Auckland
Room 2004, Level 2, M&HS Building 507
28 Park Avenue
Grafton
Auckland 1023
Query!
Country
112448
0
New Zealand
Query!
Phone
112448
0
+64 99239791
Query!
Fax
112448
0
Query!
Email
112448
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Some relevant patient information such as age, sex, ethnicity, and medical history will be published with the main study. Further data may be shared with researchers performing further research, e.g. future studies by members of the same research team on the same topic. All shared data will be de-identified. No information that could reasonably identify the patient will be shared/published.
Query!
When will data be available (start and end dates)?
After conclusion of the study and publication of the study results. No end date.
Query!
Available to whom?
Researchers performing future studies on lymphatic composition and monitoring. It may include members of the current research team who go on the do further studies into this area, and wish to compare/build upon data from the current study. Availability will be on a case-by-case basis at the discretion of Primary Sponsor.
Query!
Available for what types of analyses?
The data and results from this study can be used to help design and inform new studies that test for different lymphatic biomarkers. The results of these future studies may be cross-referenced with the results from the current study (e.g. comparing efficacy of different methods, testing for repeatability, etc.), and relevant de-identified patient information linked to the study may be used.
Query!
How or where can data be obtained?
Future research will require starting a new study for the purposes of further analysis. Access to data and information linked to the current study beyond that in published reports of the study will be subject to approval by the Principal Investigator (
[email protected]
)
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
12437
Study protocol
[email protected]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF